ENGN news & sentiment — enGene Therapeutics Inc.

MAR 17·MarketBeatMed

Short Interest in enGene Holdings Inc. (NASDAQ:ENGN) Decreases By 17.7%

enGene Holdings Inc. (NASDAQ:ENGN) experienced a 17.7% decrease in short interest during February, settling at 1,235,753 shares, representing 2.1% of shares outstanding. The short-interest ratio for the clinical-stage biopharmaceutical company is now 10.4 days. Analysts maintain a "Moderate Buy" rating with an average target price of $22.86, following recent broker activity including buy/outperform calls and a $30 target from Oppenheimer.

JAN 23·MarketBeat

enGene (NASDAQ:ENGN) Stock Price Up 11.3% - Time to Buy?

enGene (NASDAQ:ENGN) shares surged 11.3% on Thursday, trading at $10.39 with significantly higher volume than average. Analysts currently rate ENGN as a "Moderate Buy" with an average price target of $22.38, though individual ratings range from a "strong-buy" to a "sell." Despite missing quarterly EPS estimates, the clinical-stage gene-therapy company, which uses the EDV platform, maintains strong liquidity and low debt levels.

NOV 11·Benzinga

Why enGene Holdings Stock Is Trading Higher Today - enGene Holdings ( NASDAQ:ENGN )

enGene Holdings Inc. ( NASDAQ:ENGN ) stock is edging higher on Tuesday, with a session volume of 18.62 million compared to an average volume of 266.85 thousand, as per data from Benzinga Pro.

$ENGN

Short Interest in enGene Holdings Inc. (NASDAQ:ENGN) Decreases By 17.7%

enGene (NASDAQ:ENGN) Stock Price Up 11.3% - Time to Buy?

Why enGene Holdings Stock Is Trading Higher Today - enGene Holdings ( NASDAQ:ENGN )

News on $ENGN